Christopher Rajkumar
@rajkumar_chris
Interventional Cardiology Fellow | MRC Clinical Research Training Fellow | Imperial College London
Thanks to @JACCJournals and @PCRonline for showcasing, and the patients who made ORBITA-STAR possible! Hopefully a step toward more targeted treatment.
#ORBITA-STAR: Symptom-to-stenosis mapping may allow #PCI to be targeted to those most likely to benefit. Learn more in #JACC: bit.ly/4bfHcoJ #CardioTwitter @rajkumar_chris @rallamee @MikeFoley89
Had a great time at #ECAS2025 as the only interventionalist at an EP conference! Fantastic to see a full session on the placebo effect in cardiology. Thanks to the organizers for the invite @ECAS_Heart . Now to #EuroPCR @PCRonline
#EuroPCR 2025 PCR’s Got TALENT 1️⃣ 3 min / 3 slides 2️⃣ 5 min / 5 slides 3️⃣ 8 min / 8 slides 🫵 Support & VOTE ! Previous WINNERS include superstars 🌟Dr Ziad Ali 🌟Dr Dejan Milasinovic 🌟Dr Tom Ford 🌟Dr Christopher Rajkumar 📌 Starts today 12:00, Rm 252A
𝐃𝐒𝐄 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐬 𝐢𝐧 𝐎𝐑𝐁𝐈𝐓𝐀-𝟐: Stress echo ischemia identifies who 𝘳𝘦𝘢𝘭𝘭𝘺 benefits from PCI. 📖 𝐉𝐮𝐬𝐭 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝 𝐢𝐧 #𝐉𝐀𝐂𝐂: bit.ly/42PNCcB @rallamee @mshunshin @rajkumar_chris @MikeFoley89 @FloSimader @ShaynaChotai
Tons of high-value case-based presentations covering CAD arrhythmia HF shock and more. Come join! @benhibbertMDPhD @stanhenkin @aelsab @RowseMD @DrDeese99 @claireraph @rajkumar_chris @MayoCVFellows
Our annual Coronary Artery Disease course is sure to hit the jackpot with diverse and engaging topics, interactive case reviews and a hands-on #POCUS skills session. Connect with experts this October in Las Vegas: mayocl.in/3EqKMkN w/ CD @rajivxgulati & Malcolm Bell, M.D.
Great morning at @RCPhysicians talking about preventive Cardiology on the @BritishCardioSo @MayoClinicCV Cardiology Review Course Lots of old friends and great questions! @rajivxgulati @rajkumar_chris @ShouvikHaldar Sudhir Rathore, Louise Buchanan and Malcolm Bell #crc2025
Are the Appropriate Use Criteria (AUC) for revascularization still aligned with the latest evidence? New insights from ISCHEMIA challenge key assumptions. My two cents in @CircOutcomes It’s time to rethink outdated priorities. tinyurl.com/cupe7hx8
Evaluating the Appropriate Use Criteria for Coronary Revascularization in Stable Ischemic Heart Disease Using Randomized Data From the ISCHEMIA Trial #AHAJournals @GreggWStone @SripalBangalore ahajrnls.org/43iDaej
Join us at our Cardiology Review Course with @MayoClinic from Monday 10 - Friday 14 March at @RCPhysicians >> tinyurl.com/BCSMayoCRC. This five-day course is in its 17th year and provides a comprehensive opportunity to update your knowledge through lectures and interactive…
I think so, what else explains an initial high event rate which then subsides (aortic stenosis doesn’t get better!)? Great if you can manage the first 6 months of subtraction anxiety - event rate then tracks the TAVR arm. Psychology so important in clinical trials. @drjohnm
Thanks @rajkumar_chris for chiming in. For us new to the concept of subtraction anxiety: Is the suspiciously pointy corner (immediate change in slope) of the panel A&D yellow curve just before 0.5yr a finding that is pathognomonic for subtraction anxiety?
Should PCI be an option for first line management of stable angina symptoms? Point and counterpoint in @CircOutcomes with final word from @bnallamo and @TCTMD ahajournals.org/doi/full/10.11… @rallamee
Check out our journal club with @OPCILive on ORBITA-STAR and the symptom stratified analysis of ORBITA-2 @rallamee @FloSimader @ImperialNHLI
Watch This Week's Episode of OPCI Journal Club: “ORBITA-STAR Trial and the ORBITA II Symptoms Analysis” presented by @rallamee @rajkumar_chris and @FloSimader. Joined by panelists @djc795 @JWMoses @ESHLOF and Dr. Lawrence Garcia. opci.live/journal-club/ #cardiotwitter
Excellent discussion of ORBITA-STAR by @michaeltct Simple findings like those made in this study pave the way to solve a major clinical problem. In stable patients, persistent angina is PCI’s Achilles’ heel @TCTMD @PCRonline @rallamee
ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI dlvr.it/T91dpl
ORBITA-STAR at #EuroPCR is a fascinating & successful study of type of chest pain as a predictor of PCI success. Very difficult to ascertain if angina caused by ischemia is what patients felt. This was a concern of Gruentzig's 40 yrs ago! @rajkumar_chris @rallamee #AngioHistory
Always a privilege to work with incredible statisticians (and cardiologists) @f2harrell and @mshunshin. This time for ORBITA-STAR. @ImperialNHLI @ImperialNHS @JACCJournals
As a statistical modeler who does clinical research, a figure like this is a reason for being - it’s even got Bayesian uncertainty intervals.
In ORBITA-STAR, angina verification with an ischaemic stimulus powerfully predicted response to PCI. #EuroPCR2024 Perhaps we have been too focused on treatment when the problem always lay in the diagnosis! Published today in #JACC jacc.org/doi/10.1016/j.… @rallamee
Q: Does blinding matter in RCTs of surgical procedures? A: Depends on the endpoint @JAMASurgery We compared placebo-controlled and open-label surgical trials to identify when the placebo effect is most powerful @rallamee @KatieEljadi @ImperialNHLI jamanetwork.com/journals/jamas…
Amazing to see a brilliant friend and colleague @MikeFoley89 present the #ORBITA-COSMIC trial of the coronary sinus reducer with simultaneous publication in @TheLancet @rallamee @ImperialNHLI @ImperialNHS #ACC2024 thelancet.com/journals/lance…
Here we go again! Want to see if the coronary sinus reducer works in refractory angina? Watch @MikeFoley89 present the results of the ORBITA-COSMIC in the main arena at #ACC this Monday #ORBITA @fiyyazAJ @mshunshin @ShaynaChotai @rajkumar_chris @FloSimader
Exciting insights from our @BSCMR Valve Consortium, presented at #CMR2024 and featured in #EHJ: In severe AS, myocardial scar detected by #whyCMR pre-operatively is linked to long-term survival post-AVR. This underscores theimportance of fibrosis for post-op risk stratification.